Epstein-barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection.

Abstract:

:The human gammaherpesvirus family includes Epstein-Barr virus (EBV) and human herpesvirus (HHV)-8, also known as Kaposi sarcoma-associated herpesvirus (KSHV). In human immunodeficiency virus (HIV)-infected patients, both EBV and KSHV have been implicated in the development of a wide range of tumors. KSHV-associated diseases include Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease (MCD). EBV has been associated with the development of several malignancies, including Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). The introduction of highly active antiretroviral therapy (HAART) has dramatically modified the natural history of HIV infection, causing a decline in the incidence of acquired immunodeficiency syndrome (AIDS)-defining malignancies, including KS. However, it has had a less favorable impact on EBV-related malignancies and NHLs remain the most common tumors in the HAART era. In this review, we briefly summarize the pathogenesis, epidemiology, clinical features, and therapeutic approach to EBV- and KSHV-associated tumors in the setting of HIV infection.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Pinzone MR,Berretta M,Cacopardo B,Nunnari G

doi

10.1053/j.seminoncol.2014.12.026

subject

Has Abstract

pub_date

2015-04-01 00:00:00

pages

258-71

issue

2

eissn

0093-7754

issn

1532-8708

pii

S0093-7754(14)00297-8

journal_volume

42

pub_type

杂志文章,评审
  • Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.

    abstract::Cancer vaccines offer a low-toxicity approach to induce anticancer immune responses. They have shown promise for clinical benefit with one cancer vaccine approved in the United States for advanced prostate cancer. As other immune therapies are now clearly effective for treatment of advanced cancers of many histologies...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.05.006

    authors: Obeid J,Hu Y,Slingluff CL Jr

    更新日期:2015-08-01 00:00:00

  • The Bayesian basket design for genomic variant-driven phase II trials.

    abstract::Basket clinical trials are a new category of early clinical trials in which a treatment is evaluated in a population of patients with tumors of various histologic types and primary sites selected for containing specific genomic abnormalities. The objective of such studies is generally to discover histologic types in w...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2016.01.002

    authors: Simon R,Geyer S,Subramanian J,Roychowdhury S

    更新日期:2016-02-01 00:00:00

  • Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia.

    abstract::Immune dysregulation, a hallmark of chronic lymphocytic leukemia (CLL), manifests itself in three autoimmune diseases: warm autoimmune hemolytic anemia (AIHA); idiopathic thrombocytopenia (ITP); and, pure red cell aplasia (PRCA). AIHA occurs in 11% of advanced stage CLL patients. Prednisone is the first treatment of c...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Diehl LF,Ketchum LH

    更新日期:1998-02-01 00:00:00

  • Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer.

    abstract::The discovery that etoposide is one of the most active drugs in small-cell lung cancer (SCLC) led to its incorporation into a number of first-line combination chemotherapy regimens. The cyclophosphamide/doxorubicin/etoposide (CAE) regimen was shown to be as active or more active than other standard regimens in nonrand...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Bunn PA Jr,Greco FA,Einhorn L

    更新日期:1986-09-01 00:00:00

  • 3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer.

    abstract::Early detection of response to neoadjuvant chemoradiation in esophageal cancer may allow individualization of treatment strategies and avoidance of unnecessary treatment. Although positron emission tomography (PET) with [(18)F]fluorodeoxyglucose (FDG) permits detection of changes in tumor proliferation before any chan...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2007.01.002

    authors: Chao KS

    更新日期:2007-04-01 00:00:00

  • Metastatic breast cancer: preliminary results with oral hormonal therapy.

    abstract::Hormonal therapy is very effective in the treatment of patients with metastatic breast cancer. Response to various therapies leads to improved quality of life and prolonged survival. This clinical trial compared two commonly utilized additive hormonal agents, tamoxifen citrate and megestrol acetate (Megace). Prelimina...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Allegra JC,Bertino J,Bonomi P,Byrne P,Carpenter J,Catalano R,Creech R,Dana B,Durivage H,Einhorn L

    更新日期:1985-12-01 00:00:00

  • The role of monoclonal antibodies in stem cell transplantation.

    abstract::Monoclonal antibodies directed at the lymphoid antigens have become established treatments for hematological malignancies either alone or in combination with chemotherapy. However, their incorporation in the transplant setting remains investigational. This review focuses on the currently available data for in vitro an...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.11.005

    authors: Wasil T,Rai KR,Mehrotra B

    更新日期:2004-02-01 00:00:00

  • Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates.

    abstract::Transport of folates and antifolates in most cells is mediated by the reduced folate carrier (RFCI), an anion exchanging concentrative process, which is opposed by independent exit pump(s) that are directly coupled to energy metabolism. The balance of these processes governs the free intracellular folate level that is...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Sierra EE,Goldman ID

    更新日期:1999-04-01 00:00:00

  • The role of music therapy in palliative medicine and supportive care.

    abstract::This paper is designed to provide an introduction to music therapy in the continuum of cancer care. The value and use of music therapy during diagnosis and treatment, palliation, hospice, actively dying, and bereavement have been well documented. The music therapy process will be identified, research will be shared, a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2011.03.010

    authors: Gallagher LM

    更新日期:2011-06-01 00:00:00

  • Challenges in the management of stage II colon cancer.

    abstract::Approximately one third of patients diagnosed with early-stage colon cancer will present with lymph node involvement (stage III) and about one quarter with transmural bowel wall invasion but negative lymph nodes (stage II). Adjuvant chemotherapy targets micrometastatic disease to improve disease-free (DFS) and overall...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2011.05.005

    authors: Dotan E,Cohen SJ

    更新日期:2011-08-01 00:00:00

  • Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors.

    abstract::The treatment for patients with unknown primary carcinoma, particularly those with unfavorable prognosis factors, has changed in the last decade, and continues to evolve. Empiric chemotherapy trials reported since 2000 with the newer drugs have improved the overall survival compared to retrospective historical data an...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2008.10.005

    authors: Greco FA,Pavlidis N

    更新日期:2009-02-01 00:00:00

  • The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience.

    abstract::Coelomic epithelial carcinoma of the ovary, the most common cause of death from cancer of the female genital tract in the United States, presents most commonly as advanced (stage III or IV) disease. Management consists of aggressive surgical cytoreduction followed by combination chemotherapy, until recently, a platinu...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Thigpen T,Vance RB,McGuire WP,Hoskins WJ,Brady M

    更新日期:1995-12-01 00:00:00

  • Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.

    abstract::Relapse following complete remission achieved with a single course of high-dose chemotherapy continues to be the main cause of treatment failure in patients with metastatic breast cancer. A phase I/II trial was initiated that combined the two most active drugs against breast cancer, doxorubicin and paclitaxel (Taxol; ...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Rahman Z,Champlin R,Rondon G,Frye D,Valero V,Mehra R,Hortobagyi G

    更新日期:1997-10-01 00:00:00

  • Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer--preliminary results of a randomized trial.

    abstract::Patients with advanced colorectal cancer were randomized to receive either fluorouracil (5-FU) 370 mg/m2 IV days 1 to 5 followed by weekly applications of 5-FU 600 mg/m2 or the same doses of 5-FU preceded by folinic acid 200 mg/m2. Because of toxicity, the weekly 5-FU dose in the combination treatment schedule was red...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Steinke B,Günther E,Hirschmann WD,Sondern W,Koniczek KH,Wander HE,Natt F,Wagner T,Hinrichs HF,Werdier D

    更新日期:1992-04-01 00:00:00

  • Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19.

    abstract::This article summarizes the likely attenuation properties of RRx-001 in COVID-19 based on its mechanism of action and the putative pathogenesis of the disease, which appears to activate inflammatory, oxidative, and immune cascades with the potential to culminate in acute respiratory distress syndrome, cytokine storm a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2020.07.002

    authors: Oronsky B,Knox S,Cabrales P,Oronsky A,Reid TR

    更新日期:2020-10-01 00:00:00

  • Kinetic concepts in the systemic drug therapy of breast cancer.

    abstract::Optimal management of cancer today requires a thorough and up-to-date understanding of cancer cell kinetics and biochemistry. This report reviews the history and current standards in these fields and how they affect the contemporary approach to breast cancer management. Also outlined are recommended avenues for future...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Norton L

    更新日期:1999-02-01 00:00:00

  • New antimetabolites in the treatment of human malignancies.

    abstract::Several new antimetabolites have been evaluated in clinical trials in recent years. Those with the most promising activity include the structurally related purine analogs fludarabine, 2-chlorodeoxyadenosine, and 2'-deoxycoformycin. These compounds have shown impressive activity against a broad spectrum of indolent lym...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Cheson BD

    更新日期:1992-12-01 00:00:00

  • Inflammatory breast cancer: patient advocate view.

    abstract::Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer, often presenting with distant metastasis. While controversy exists regarding the actual incidence of the disease, there is agreement that IBC causes a disproportionate number of breast cancer deaths. Those with typical IBC symptoms face a h...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2007.11.011

    authors: Mason G,Johnson O

    更新日期:2008-02-01 00:00:00

  • Cyclooxygenase-2 inhibitors in colorectal cancer.

    abstract::Cyclooxygenase (COX) enzyme-dependent arachidonic acid metabolites occupy key positions in important physiologic processes such as immunity, reproduction, and vascular integrity. Large retrospective and prospective population-based studies have shown that the use of both nonselective, nonsteroidal anti-inflammatory dr...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00120-9

    authors: Stoehlmacher J,Lenz HJ

    更新日期:2003-06-01 00:00:00

  • Defining the clinical diagnosis of inflammatory breast cancer.

    abstract::Inflammatory breast cancer (IBC) is an extremely aggressive disease that progresses rapidly and carries a very grim prognosis. It is characterized by erythema, rapid enlargement of the breast, skin ridging, and a characteristic peau d'orange appearance of the skin secondary to dermal lymphatic tumor involvement. Altho...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2007.11.010

    authors: Singletary SE,Cristofanilli M

    更新日期:2008-02-01 00:00:00

  • Screening diagnosis and staging of esophageal cancer.

    abstract::In geographic areas where there is a high risk of esophageal cancer, analysis of cells obtained from the esophagus has been used effectively to detect early lesions. This has been demonstrated on a large scale in studies from China. Using abrasive balloon cytology techniques, 75% of the cancers detected were early les...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Lightdale CJ,Winawer SJ

    更新日期:1984-06-01 00:00:00

  • Lymphoma: diagnosis, staging, natural history, and treatment strategies.

    abstract::Non-Hodgkin's lymphoma (NHL) is not a single disease, but a group of closely related B- and T-cell cancers of the lymphatic system. The incidence of NHL is rising, particularly in the countries of the industrialized world. The increased incidence is poorly understood, but several risk factors have been postulated to b...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2005.01.008

    authors: Zinzani PL

    更新日期:2005-02-01 00:00:00

  • Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.

    abstract::Combinations of active antineoplastic agents have been the most effective treatment for metastatic breast cancer. Criteria for an effective combination include use of drugs with different mechanisms of action, nonoverlapping toxic effects, and synergistic, or at least additive, antitumor activity. Paclitaxel (Taxol; B...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Holmes FA

    更新日期:1996-10-01 00:00:00

  • Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy.

    abstract::For four decades, 5-fluorouracil was the only option available for patients with metastatic colorectal cancer. It provided a response rate of 15% to 20%, with a median survival of approximately 1 year. In the past 5 years, remarkable progress has been made in colorectal cancer research with the approval of irinotecan ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.04.022

    authors: Varadhachary GR,Hoff PM

    更新日期:2005-12-01 00:00:00

  • Measuring quality of life: an emerging science.

    abstract::Quality of life (QOL) variables are increasingly included as end points in cancer therapy trials, supplementing such traditional end points as survival time in evaluating the effects of cancer treatments. Consensus has been reached that a number of QOL components (symptom status and physical, emotional, role, and soci...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Moinpour CM

    更新日期:1994-10-01 00:00:00

  • Treatment of newly diagnosed myeloma: Bortezomib-based triplet.

    abstract::We review the options for the treatment of newly diagnosed myeloma in a patient who is a candidate for autologous stem cell transplantation (ASCT). Bortezomib, lenalidomide, dexamethasone (VRD) has been studied in two randomized trials as first-line therapy. In one of these trials, VRD demonstrated improved overall su...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2016.11.003

    authors: Rajan AM,Rajkumar SV

    更新日期:2016-12-01 00:00:00

  • Maintaining bone health in prostate cancer throughout the disease continuum.

    abstract::Prostate cancer (PC) is the most prevalent malignancy in men, with 604,506 new cases diagnosed yearly worldwide. Maintaining bone health is important during all stages of PC, including patients who experience bone loss from androgen-deprivation therapy and patients who develop bone metastases. Patients with bone metas...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2010.06.007

    authors: Saad F,Eastham J

    更新日期:2010-06-01 00:00:00

  • Factors influencing quality of life in cancer patients: anemia and fatigue.

    abstract::Anemia is a multi-symptom syndrome involving both physical and emotional problems that can be evaluated for their impact on quality of life. Fatigue is the cardinal symptom of anemia, reported by three of four cancer patients using the general version of the Functional Assessment of Cancer Therapy (FACT-G) questionnai...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Cella D

    更新日期:1998-06-01 00:00:00

  • Recommendations of follow-up after treatment of germ cell tumors.

    abstract::Patients diagnosed with germ cell tumors (GCT) are relatively young, and most are rendered disease-free by primary treatment. Also, second-line therapies in nearly all instances are potentially curative. Therefore, the schedule and modalities of follow-up testing are important issues in detecting recurrence of GCT and...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00098-8

    authors: Kondagunta GV,Sheinfeld J,Motzer RJ

    更新日期:2003-06-01 00:00:00

  • Treatment of hypercalcemia of malignancy with bisphosphonates.

    abstract::Hypercalcemia of malignancy (HCM) is a potentially life-threatening complication of cancer resulting from increased bone resorption by osteoclasts. Clinical management of HCM primarily consists of intravenous rehydration therapy combined with pharmaceutical agents that decrease osteoclast activity. Several generations...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.37417

    authors: Berenson JR

    更新日期:2002-12-01 00:00:00